Patients who received intravitreal aflibercept injections as needed for macular edema due to central retinal vein occlusion showed loss of visual and anatomic improvements at 100 weeks, according to the COPERNICUS study.
The study is an ongoing investigation in which patients were evaluated at week 24, week 52 and week 100.
The phase 3 randomized, double-masked trial included 188 patients with macular edema secondary to CRVO. Initially, 114 patients received a 2-mg dose of Eylea (aflibercept, Regeneron Pharmaceuticals) and 74 patients received sham injections every 4 weeks until week 24. From week 24 to week 52, patients received aflibercept injections as needed and were evaluated monthly. From week 52 to week 100, patients received aflibercept injections as needed and were evaluated quarterly.Full Story »